Preoperative oral antibiotic prophylaxis reduces Pseudomonas aeruginosa surgical site infections after elective colorectal surgery: a multicenter prospective cohort study

Abstract

BackgroundHealthcare-associated infections caused by Pseudomonas aeruginosa are associated with poor outcomes. However, the role of P. aeruginosa in surgical site infections after colorectal surgery has not been evaluated. The aim of this study was to determine the predictive factors and outcomes of surgical site infections caused by P. aeruginosa after colorectal surgery, with special emphasis on the role of preoperative oral antibiotic prophylaxis.MethodsWe conducted an observational, multicenter, prospective cohort study of all patients undergoing elective colorectal surgery at 10 Spanish hospitals (2011–2014). A logistic regression model was used to identify predictive factors for P. aeruginosa surgical site infections.ResultsOut of 3701 patients, 669 (18.1%) developed surgical site infections, and 62 (9.3%) of these were due to P. aeruginosa. The following factors were found to differentiate between P. aeruginosa surgical site infections and those caused by other microorganisms: American Society of Anesthesiologists’ score III–IV (67.7% vs 45.5%, p = 0.001, odds ratio (OR) 2.5, 95% confidence interval (95% CI) 1.44–4.39), National Nosocomial Infections Surveillance risk index 1–2 (74.2% vs 44.2%, p < 0.001, OR 3.6, 95% CI 2.01–6.56), duration of surgery ≥75thpercentile (61.3% vs 41.4%, p = 0.003, OR 2.2, 95% CI 1.31–3.83) and oral antibiotic prophylaxis (17.7% vs 33.6%, p = 0.01, OR 0.4, 95% CI 0.21–0.83). Patients with P. aeruginosa surgical site infections were administered antibiotic treatment for a longer duration (median 17 days [interquartile range (IQR) 10–24] vs 13d [IQR 8–20], p = 0.015, OR 1.1, 95% CI 1.00–1.12), had a higher treatment failure rate (30.6% vs 20.8%, p = 0.07, OR 1.7, 95% CI 0.96–2.99), and longer hospitalization (median 22 days [IQR 15–42] vs 19d [IQR 12–28], p = 0.02, OR 1.1, 95% CI 1.00–1.17) than those with surgical site infections due to other microorganisms. Independent predictive factors associated with P. aeruginosa surgical site infections were the National Nosocomial Infections Surveillance risk index 1–2 (OR 2.3, 95% CI 1.03–5.40) and the use of oral antibiotic prophylaxis (OR 0.4, 95% CI 0.23–0.90).ConclusionsWe observed that surgical site infections due to P. aeruginosa are associated with a higher National Nosocomial Infections Surveillance risk index, poor outcomes, and lack of preoperative oral antibiotic prophylaxis. These findings can aid in establishing specific preventive measures and appropriate empirical antibiotic treatment.

Pseudomonas aeruginosa Biofilms

“…Pseudomonas aeruginosa is an ubiquitous Gram-negative bacterium that causes nosocomial infections, as well as fatal infections in immunocompromised individuals, such as patients with cancer, post-surgery, severe burns or infected by human immunodeficiency virus (HIV) [ 1 , 2 , 3 ]. In 2017, P. aeruginosa was recognised as one of the most life-threatening bacteria and listed as priority pathogen for Research and Development of new antibiotics by the World Health Organization [ 4 ].…”

New Clinical Applications of Electrolyzed Water: A Review

“…Furthermore, surgical site infections can sometimes be superficial infections involving the skin [ 6 , 7 ]. At the same time, infections in other surgical sites could be more serious, which may involve tissues under the skin, organs, or even implanted materials [ 8 , 9 ]. Infections also increase the length of stay, readmission rates, costs, and even mortality [ 10 , 11 ].…”

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma

“… 25 Apatinib has anti-tumor potential against many tumors types, including hepatocellular carcinoma, gastric, non-small cell lung, and breast cancers. 26–28 To date, few studies on malignant melanoma treatment using apatinib exist. Therefore, our study investigated the anti-tumor effect of apatinib on malignant melanoma.…”